ClinicalTrials.gg
RecruitingNCT07007078Updated Jun 5, 2025

Efficacy of Dihydroartemisinin for Treating Acne Vulgaris

An Early Phase 1 interventional study of dihydroartemisinin in Acne Vulgaris, sponsored by Shanghai Zhongshan Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2025-06-05.

Sponsored by Shanghai Zhongshan Hospital · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 35 studies in Acne Vulgaris with a site in China — 8 open to participants now, 10 under way, 2 of them phase 3. Acne Vulgaris · China.

Planned enrollment
21st of 33
60 · median 100
Started
2025
with 6 others
Phase 1
4 of 35
1 open now
Registered
28th of 35
by date

Among the 35 studies in Acne Vulgaris with a site in China, this one is the 21st largest by planned enrollment of the 33 interventional ones that give a count, is one of 7 that started in 2025, is one of 4 in phase 1, and was the 28th registered.

Acne Vulgaris

795 studies on the registry are indexed under Acne Vulgaris; 96 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

8 of the 35 studies in Acne Vulgaris with a site in China are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 48 Acne Vulgaris studies recruiting now, 17 (35%) set no upper age limit and 30 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 18 Years to 40 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Acne Vulgaris with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if dihydroartemisinin (DHA) works to treat Acne Vulgaris in adults. The main question it aims to answer is:

  • Does DHA improve the acne severity by at least one grade after treatment. Researchers will treat patients who are clinically diagnosed as Acne Vulgaris to see if DHA works to alleviate the symptoms of Acne Vulgaris.

Participants will:

  • Take DHA every day for 3 months
  • Visit the clinic once every month for checkups and tests
03

Conditions studied

  • Acne Vulgaris

Browse trials for

Keywords

  • acne vulgaris
  • dihydroartemisinin
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinically diagnosed with acne vulgaris;
  • For female patients, no pregnancy plans within the next 6 months.

Exclusion criteria

Exclusion Criteria:

  • Patients who have used sex hormones or other systemic medications for acne treatment within the past 3 months;
  • Patients who have used topical medications for acne within the past 2 weeks;
  • Pregnant or breastfeeding women;
  • Patients with known severe diseases of vital organs (e.g., heart, liver, kidney) or .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    DHA (dihydroartemisinin) Arm

    Drug: dihydroartemisinin

Interventions

06

What researchers measure

Primary outcomes

  1. Improvement of acne severity by Investigator's Global Assessment (IGA)

    Improvement of acne severity is considered clinically significant if a subject's IGA improves by at least one grade

    Time frame: Before and immediately after 90-day treatment

Secondary outcomes

  1. Change of Global Acne Grading System (GAGS) score from baseline to the end of treatment

    An improvement of ≥30% in the GAGS score will be considered significant

    Time frame: Before and immediately after 90-day treatment

  2. Change of inflammatory lesion count from baseline to the end of treatment

    Time frame: Before and immediately after 90-day treatment

  3. Change of non-inflammatory lesion count from baseline to the end of treatment

    Time frame: Before and immediately after 90-day treatment

  4. Number of participants who achieved an IGA score of 0 or 1 at the end of treatment

    Time frame: Before and immediately after 90-day treatment

  5. Change of serum total testosterone from baseline to the end of treatment

    Time frame: Before and immediately after 90-day treatment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All IPD that underlie results in a publication

Supporting information: Study protocol, Statistical analysis plan

Time frame: After publication

Access criteria: IPD and supporting information will be avaible to researchers upon reasonable request (e.g. with a practical and meaningful research proposal).

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2025; primary completion for May 2026, 11 months later.

Of 51 phase 1 interventional studies under Acne Vulgaris, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 10. This study's planned 11 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2025
First posted
Jun 5, 2025
StartEst.
Jun 2025
Primary completionEst.
May 2026
CompletionEst.
Dec 2026
Last update
Jun 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07007078
Responsible party
Sponsor
First posted
Jun 5, 2025
Start date
Jun 2025 (estimated)
Primary completion
May 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jun 5, 2025

Study contacts

Lujuan GAO, MD, PhD
Contact
gao.lujuan@zs-hospital.sh.cn
86-021-64041990
Jingjing JIANG, MD, PhD
principal investigator · Fudan University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Artenimol

Start the discussion